{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:16:52Z","timestamp":1792649812680,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007797","name":"University of Helsinki","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The renin\u2013angiotensin system (RAS) has been increasingly recognized to be associated with carcinogenesis and cancer progression. There is extensive preclinical evidence suggesting the benefits of RAS-inhibiting drugs, such as angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs), in preventing the progression of gastric cancer (GC). However, clinical evidence supporting the positive effects of ARBs and ACEIs on GC prognosis is currently limited. The purpose of this study is to investigate their effects in a Finnish cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective national cohort study, where cancer patient registry data were linked to prescription purchase records for ARBs and ACEIs. The effect of ARB\/ACEI in the post-diagnostic period on overall mortality was assessed using Cox regression analysis. Disease-specific mortality associations were evaluated with the Fine and Gray model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 2246 histologically confirmed GC patients diagnosed between 2011 and 2016. Follow-up continued until the end of 2023. In the main analysis, a protective effect of ARB use was associated with a significant reduction in overall mortality (adjusted hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.69\u20130.94,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007). Furthermore, the effect was greater for those with higher ARB dosage. A similar finding was not observed with ACEI use. For disease-specific survival, both ARB and ACEI use had a significant protective effect (adjusted HR 0.75, 95% CI 0.62\u20130.90\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002 and adjusted HR 0.76, 95% CI 0.63\u20130.93,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.007, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study adds to the evidence that ARB use might have a beneficial impact on survival among GC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10120-025-01662-2","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T14:43:43Z","timestamp":1758379423000},"page":"1058-1066","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Angiotensin receptor blocker and angiotensin-converting enzyme inhibitor use and survival in gastric cancer patients: a Finnish nationwide cohort study"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3681-3058","authenticated-orcid":false,"given":"Aliisa","family":"Auvinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panu","family":"Aaltonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harri","family":"Mustonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caj","family":"Haglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauli","family":"Puolakkainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Sepp\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"issue":"3","key":"1662_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10125","key":"1662_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nik\u0161i\u0107 M, et al. Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023\u201375.","journal-title":"Lancet"},{"issue":"3","key":"1662_CR3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1152\/physrev.00036.2005","volume":"86","author":"M Paul","year":"2006","unstructured":"Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86(3):747\u2013803.","journal-title":"Physiol Rev"},{"issue":"9","key":"1662_CR4","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1093\/carcin\/bgn171","volume":"29","author":"EI Ager","year":"2008","unstructured":"Ager EI, Neo J, Christophi C. The renin\u2013angiotensin system and malignancy. Carcinogenesis. 2008;29(9):1675\u201384.","journal-title":"Carcinogenesis"},{"issue":"11","key":"1662_CR5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nrc2945","volume":"10","author":"AJ George","year":"2010","unstructured":"George AJ, Thomas WG, Hannan RD. The renin\u2013angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010;10(11):745\u201359.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"1662_CR6","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.4161\/cbt.6.8.4412","volume":"6","author":"S Carl-McGrath","year":"2007","unstructured":"Carl-McGrath S, Ebert MPA, Lendeckel U, Rocken C. Expression of the local angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread. Cancer Biol Ther. 2007;6(8):1229\u201337.","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"1662_CR7","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3892\/ijo_00000287","volume":"34","author":"J Kinoshita","year":"2009","unstructured":"Kinoshita J, Fushida S, Harada S, Yagi Y, Fujita H, Kinami S, et al. Local angiotensin II-generation in human gastric cancer: Correlation with tumor progression through the activation of ERK1\/2, NF-\u03baB and survivin. Int J Oncol. 2009;34(6):1573\u201382.","journal-title":"Int J Oncol"},{"key":"1662_CR8","doi-asserted-by":"crossref","unstructured":"R\u00f6cken C, R\u00f6hl FW, Diebler E, Lendeckel U, Pross M, Carl-McGrath S, et al. The Angiotensin II\/Angiotensin II Receptor System Correlates with Nodal Spread in Intestinal Type Gastric Cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1206\u201312.","DOI":"10.1158\/1055-9965.EPI-05-0934"},{"key":"1662_CR9","doi-asserted-by":"crossref","unstructured":"Huang MM, Guo AB, Sun JF, Chen XL, Yin ZY. Angiotensin II promotes the progression of human gastric cancer. Mol Med Rep. 2014;9(3):1056\u201360.","DOI":"10.3892\/mmr.2014.1891"},{"key":"1662_CR10","doi-asserted-by":"crossref","unstructured":"Wang L, Cai S rong, Zhang C hua, He Y long, Zhan W hua, Wu H, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model. Chin Med J. 2008;121(21):2167.","DOI":"10.1097\/00029330-200811010-00012"},{"key":"1662_CR11","doi-asserted-by":"crossref","unstructured":"Okazaki M, Fushida S, Harada S, Tsukada T, Kinoshita J, Oyama K, et al. The Angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer. Cancer Lett. 2014;355(1):46\u201353.","DOI":"10.1016\/j.canlet.2014.09.019"},{"key":"1662_CR12","doi-asserted-by":"crossref","unstructured":"Fujita N, Fujita K, Iwama H, Kobara H, Fujihara S, Chiyo T, et al. Antihypertensive drug telmisartan suppresses the proliferation of gastric cancer cells in vitro and in vivo. Oncol Rep. 2020;44(1):339\u201348.","DOI":"10.3892\/or.2020.7607"},{"issue":"1","key":"1662_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1177\/1470320310379066","volume":"12","author":"P Hallersund","year":"2011","unstructured":"Hallersund P, Elfvin A, Helander HF, F\u00e4ndriks L. The expression of renin-angiotensin system components in the human gastric mucosa. J Renin Angiotensin Aldosterone Syst. 2011;12(1):54\u201364.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"10","key":"1662_CR14","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00535-011-0433-7","volume":"46","author":"M Sugimoto","year":"2011","unstructured":"Sugimoto M, Ohno T, Yamaoka Y. Expression of angiotensin II type 1 and type 2 receptor mRNAs in the gastric mucosa of Helicobacter pylori-infected Mongolian gerbils. J Gastroenterol. 2011;46(10):1177\u201386.","journal-title":"J Gastroenterol"},{"issue":"1","key":"1662_CR15","first-page":"13","volume":"81","author":"F Ender","year":"1993","unstructured":"Ender F, Labancz T, Rosivall L. Protective effects of the inhibition of the renin-angiotensin system against gastric mucosal lesions induced by cold-restraint in the rat. Acta Physiol Hung. 1993;81(1):13\u20138.","journal-title":"Acta Physiol Hung"},{"issue":"2","key":"1662_CR16","doi-asserted-by":"publisher","first-page":"G414","DOI":"10.1152\/ajpgi.00058.2003","volume":"285","author":"C Bregonzio","year":"2003","unstructured":"Bregonzio C, Armando I, Ando H, Jezova M, Baiardi G, Saavedra JM. Anti-inflammatory effects of angiotensin II AT1 receptor antagonism prevent stress-induced gastric injury. Am J Physiol Gastrointest Liver Physiol. 2003;285(2):G414\u201323.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"5","key":"1662_CR17","first-page":"1210","volume":"23","author":"J Griniatsos","year":"2018","unstructured":"Griniatsos J, Trafalis D. Differences in gastric cancer surgery outcome between East and West: differences in surgery or different diseases? J BUON. 2018;23(5):1210\u20135.","journal-title":"J BUON"},{"issue":"12","key":"1662_CR18","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1080\/0284186X.2023.2259081","volume":"62","author":"P Aaltonen","year":"2023","unstructured":"Aaltonen P, Mustonen H, Peltola K, Carp\u00e9n O, Puolakkainen P, Haglund C, et al. The impact of implementing current treatment modalities and female sex on gastric cancer outcomes, 2000\u20132016: a longitudinal nationwide cohort study. Acta Oncol. 2023;62(12):1732\u201341.","journal-title":"Acta Oncol"},{"key":"1662_CR19","unstructured":"Nomesco N. NOMESCO classification of Surgical Procedures (NCSP), version 1.16 [Internet]. 2011 [cited 2024 May 8]. Available from: https:\/\/urn.kb.se\/resolve?urn=urn:nbn:se:norden:org:diva-4605"},{"key":"1662_CR20","unstructured":"WHO ATC\/DDD Index [Internet]. [cited 2024 May 6]. Available from: https:\/\/atcddd.fhi.no\/atc_ddd_index\/"},{"issue":"4","key":"1662_CR21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3390\/cancers13040696","volume":"13","author":"A Siltari","year":"2021","unstructured":"Siltari A, Auvinen A, Murtola TJ. Pharmacoepidemiological evaluation in prostate cancer\u2014common pitfalls and how to avoid them. Cancers (Basel). 2021;13(4):696.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1662_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3109\/02841869409098430","volume":"33","author":"L Teppo","year":"1994","unstructured":"Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry: experience in Finland. Acta Oncol. 1994;33(4):365\u20139.","journal-title":"Acta Oncol"},{"issue":"3","key":"1662_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/00365521.2020.1867893","volume":"56","author":"P Lunkka","year":"2021","unstructured":"Lunkka P, Malila N, Ryyn\u00e4nen H, Heikkinen S, Sallinen V, Koskenvuo L. Accuracy of Finnish cancer registry colorectal cancer data: a comparison between registry data and clinical records. Scand J Gastroenterol. 2021;56(3):247\u201351.","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"1662_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"11","key":"1662_CR25","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care"},{"key":"1662_CR26","doi-asserted-by":"publisher","first-page":"923","DOI":"10.2147\/CLEP.S218697","volume":"11","author":"J Pylv\u00e4l\u00e4inen","year":"2019","unstructured":"Pylv\u00e4l\u00e4inen J, Talala K, Murtola T, Taari K, Raitanen J, Tammela TL, et al. Charlson comorbidity index based on hospital episode statistics performs adequately in predicting mortality, but its discriminative ability diminishes over time. Clin Epidemiol. 2019;11:923\u201332.","journal-title":"Clin Epidemiol"},{"issue":"1","key":"1662_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/sim.4780030106","volume":"3","author":"R Simon","year":"1984","unstructured":"Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3(1):35\u201344.","journal-title":"Stat Med"},{"key":"1662_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejca.2020.02.017","volume":"130","author":"RT van der Kaaij","year":"2020","unstructured":"van der Kaaij RT, Koemans WJ, van Putten M, Snaebjornsson P, Luijten JCHBM, van Dieren JM, et al. A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015. Eur J Cancer. 2020;130:23\u201331.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1662_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/apt.14388","volume":"47","author":"J Busby","year":"2018","unstructured":"Busby J, McMenamin \u00da, Spence A, Johnston BT, Hughes C, Cardwell CR. Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study. Aliment Pharmacol Ther. 2018;47(2):279\u201388.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"1662_CR30","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1093\/aje\/kwz106","volume":"188","author":"Y Cui","year":"2019","unstructured":"Cui Y, Wen W, Zheng T, Li H, Gao YT, Cai H, et al. Use of antihypertensive medications and survival rates for breast, colorectal, lung, or stomach cancer. Am J Epidemiol. 2019;188(8):1512\u201328.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"1662_CR31","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12885-022-09513-4","volume":"22","author":"PC Li","year":"2022","unstructured":"Li PC, Huang RY, Yang YC, Hsieh KP, Yang YH. Prognostic impact of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in esophageal or gastric cancer patients with hypertension\u2014a real-world study. BMC Cancer. 2022;22(1):430.","journal-title":"BMC Cancer"},{"issue":"151","key":"1662_CR32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bcp.2018.03.008","volume":"1","author":"S Ishikane","year":"2018","unstructured":"Ishikane S, Takahashi-Yanaga F. The role of angiotensin II in cancer metastasis: Potential of renin-angiotensin system blockade as a treatment for cancer metastasis. Biochem Pharmacol. 2018;1(151):96\u2013103.","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"1662_CR33","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1158\/1078-0432.CCR-04-1922","volume":"11","author":"C R\u00f6cken","year":"2005","unstructured":"R\u00f6cken C, Lendeckel U, Dierkes J, Westphal S, Carl-McGrath S, Peters B, et al. The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion\/deletion polymorphism. Clin Cancer Res. 2005;11(7):2526\u201330.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1662_CR34","first-page":"375","volume":"22","author":"M Cavaleiro-Pinto","year":"2011","unstructured":"Cavaleiro-Pinto M, Peleteiro B, Lunet N, Barros H. Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis. Cancer Causes Control. 2011;22(3):375\u201387.","journal-title":"Cancer Causes Control"},{"key":"1662_CR35","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fmicb.2015.00412","volume":"6","author":"K-I Mukaisho","year":"2015","unstructured":"Mukaisho K-I, Nakayama T, Hagiwara T, Hattori T, Sugihara H. Two distinct etiologies of gastric cardia adenocarcinoma: interactions among pH, Helicobacter pylori, and bile acids. Front Microbiol. 2015;6:412.","journal-title":"Front Microbiol"},{"issue":"3","key":"1662_CR36","first-page":"34","volume":"16","author":"X Wang","year":"2020","unstructured":"Wang X, Sweigert P, Eguia E, Varsnik MA, Renz CR, Terrasse WA, et al. Impact of angiotensin system inhibitors on esophageal cancer survival. Surg Open Sci. 2020;16(3):34\u20138.","journal-title":"Surg Open Sci"},{"issue":"4","key":"1662_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056320","volume":"12","author":"U Maharjan","year":"2022","unstructured":"Maharjan U, Kauppila JH. Gastric cancer completeness in Finnish Cancer Registry and Finnish patient registry: a population-based nationwide retrospective cohort study. BMJ Open. 2022;12(4):e056320.","journal-title":"BMJ Open"},{"issue":"6","key":"1662_CR38","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/1403494812456637","volume":"40","author":"R Sund","year":"2012","unstructured":"Sund R. Quality of the Finnish Hospital discharge register: a systematic review. Scand J Public Health. 2012;40(6):505\u201315.","journal-title":"Scand J Public Health"},{"issue":"77","key":"1662_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2017.02.017","volume":"1","author":"MK Leinonen","year":"2017","unstructured":"Leinonen MK, Miettinen J, Heikkinen S, Pitk\u00e4niemi J, Malila N. Quality measures of the population-based Finnish cancer registry indicate sound data quality for solid malignant tumours. Eur J Cancer. 2017;1(77):31\u20139.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1662_CR40","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/0284186X.2017.1407039","volume":"57","author":"E Pukkala","year":"2018","unstructured":"Pukkala E, Engholm G, H\u00f8jsgaard Schmidt LK, Storm H, Khan S, Lambe M, et al. Nordic cancer registries\u2014an overview of their procedures and data comparability. Acta Oncol. 2018;57(4):440\u201355.","journal-title":"Acta Oncol"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01662-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01662-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01662-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:28:58Z","timestamp":1763562538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01662-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1662"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01662-2","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,20]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the National Institute for Health and Welfare (THL\/1255\/5.05.00\/2018), Statistics Finland (TK-52-832-19), and the Helsinki University Hospital (\u00a791 HUS\/419\/2018). As a retrospective study, informed consent was waived in accordance with Finnish legislation concerning secondary use of health data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}